[1]
Villafuerte-Gutierrez P, Villalon L, Losa JE, Henriquez-Camacho C. Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update. Advances in hematology. 2014:2014():986938. doi: 10.1155/2014/986938. Epub 2014 Nov 27 [PubMed PMID: 25525436]
[2]
Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011 Feb 15:52(4):e56-93. doi: 10.1093/cid/cir073. Epub [PubMed PMID: 21258094]
[3]
Rivera-Salgado D, Valverde-Muñoz K, Ávila-Agüero ML. [Febrile neutropenia in cancer patients: management in the emergency room]. Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia. 2018:35(1):62-71. doi: 10.4067/s0716-10182018000100062. Epub [PubMed PMID: 29652973]
[4]
Hakim H, Flynn PM, Knapp KM, Srivastava DK, Gaur AH. Etiology and clinical course of febrile neutropenia in children with cancer. Journal of pediatric hematology/oncology. 2009 Sep:31(9):623-9. doi: 10.1097/MPH.0b013e3181b1edc6. Epub [PubMed PMID: 19644403]
[5]
Holland T, Fowler VG Jr, Shelburne SA 3rd. Invasive gram-positive bacterial infection in cancer patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014 Nov 15:59 Suppl 5(Suppl 5):S331-4. doi: 10.1093/cid/ciu598. Epub [PubMed PMID: 25352626]
[6]
Raad I, Chaftari AM. Advances in prevention and management of central line-associated bloodstream infections in patients with cancer. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014 Nov 15:59 Suppl 5():S340-3. doi: 10.1093/cid/ciu670. Epub [PubMed PMID: 25352628]
[7]
Gudiol C, Bodro M, Simonetti A, Tubau F, González-Barca E, Cisnal M, Domingo-Domenech E, Jiménez L, Carratalà J. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2013 May:19(5):474-9. doi: 10.1111/j.1469-0691.2012.03879.x. Epub 2012 Apr 24 [PubMed PMID: 22524597]
[8]
van der Velden WJ, Herbers AH, Netea MG, Blijlevens NM. Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis. British journal of haematology. 2014 Nov:167(4):441-52. doi: 10.1111/bjh.13113. Epub 2014 Sep 6 [PubMed PMID: 25196917]
[9]
Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J, ESMO Guidelines Committee. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Sep:27(suppl 5):v111-v118 [PubMed PMID: 27664247]
[10]
Kitanovski L, Jazbec J, Hojker S, Derganc M. Diagnostic accuracy of lipopolysaccharide-binding protein for predicting bacteremia/clinical sepsis in children with febrile neutropenia: comparison with interleukin-6, procalcitonin, and C-reactive protein. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2014 Jan:22(1):269-77. doi: 10.1007/s00520-013-1978-1. Epub 2013 Sep 21 [PubMed PMID: 24057110]
[11]
Ahn S, Rice TW, Yeung SJ, Cooksley T. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2018 May:26(5):1465-1470. doi: 10.1007/s00520-017-3985-0. Epub 2017 Nov 22 [PubMed PMID: 29168032]
[12]
Lucas AJ, Olin JL, Coleman MD. Management and Preventive Measures for Febrile Neutropenia. P & T : a peer-reviewed journal for formulary management. 2018 Apr:43(4):228-232 [PubMed PMID: 29622943]
[13]
Libuit J, Whitman A, Wolfe R, Washington CS. Empiric vancomycin use in febrile neutropenic oncology patients. Open forum infectious diseases. 2014 Mar:1(1):ofu006. doi: 10.1093/ofid/ofu006. Epub 2014 Apr 10 [PubMed PMID: 25734080]
[14]
Yoshida M, Ohno R. Antimicrobial prophylaxis in febrile neutropenia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2004 Jul 15:39 Suppl 1():S65-7 [PubMed PMID: 15250025]
[15]
Chung SJ, Miller RA, Permpalung N, Baker AW, Diehl LF, Rizzieri DA, Alexander BD. Fluoroquinolone prophylaxis reduces febrile neutropenia, bloodstream infections from mucosal translocations, and intensive care admissions in high risk hematological patients, a single center experience. Leukemia & lymphoma. 2019 Feb:60(2):488-492. doi: 10.1080/10428194.2018.1488252. Epub 2018 Aug 21 [PubMed PMID: 30126315]
[16]
Neumann S, Krause SW, Maschmeyer G, Schiel X, von Lilienfeld-Toal M, Infectious Diseases Working Party (AGIHO), German Society of Hematology and Oncology (DGHO). Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Annals of hematology. 2013 Apr:92(4):433-42. doi: 10.1007/s00277-013-1698-0. Epub 2013 Feb 15 [PubMed PMID: 23412562]
[17]
Hashiguchi Y, Kasai M, Fukuda T, Ichimura T, Yasui T, Sumi T. Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. Anti-cancer drugs. 2015 Nov:26(10):1054-60. doi: 10.1097/CAD.0000000000000279. Epub [PubMed PMID: 26267078]
[18]
Ahn S, Lee YS. Predictive factors for poor prognosis febrile neutropenia. Current opinion in oncology. 2012 Jul:24(4):376-80. doi: 10.1097/CCO.0b013e328352ead2. Epub [PubMed PMID: 22476191]
[19]
Rosa RG, Goldani LZ. Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia. Antimicrobial agents and chemotherapy. 2014 Jul:58(7):3799-803. doi: 10.1128/AAC.02561-14. Epub 2014 Apr 21 [PubMed PMID: 24752269]
[20]
Monroe K, Cohen CT, Whelan K, King A, Maloney L, Deason J, Nichols JC, Friedman GK, Kutny M, Hayes L. Quality Initiative to Improve time to Antibiotics for Febrile Pediatric Patients with Potential Neutropenia. Pediatric quality & safety. 2018 Jul-Aug:3(4):e095. doi: 10.1097/pq9.0000000000000095. Epub 2018 Aug 9 [PubMed PMID: 30229205]